Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Docetaxel + VIC-1911 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 12 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
VIC-1911 | TAS-119|TAS-2104 | Aurka Inhibitors 24 | VIC-1911 (TAS-119) is a selective inhibitor of the serine/threonine kinase Aurora A, which may cause disruption of mitotic spindle assembly and chromosome segregation, thus inhibiting cell division and inducing apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Advanced Solid Tumor | not applicable | Docetaxel + VIC-1911 | Preclinical | Actionable | In a preclinical study, TAS-119 demonstrated synergistic effects with Taxol (paclitaxel) or Taxotere (docetaxel) in multiple tumor cell lines by promoting apoptosis (Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A268). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|